CVS Health's Caremark, one of the largest pharmacy benefit managers in the country, has settled with the Federal Trade Commission and agreed to a set of rules that could reshape how millions of insured Americans pay for prescription drugs. The FTC says the deal will save consumers billions. The details matter more than the headline.

The problem TrumpRx ran into

President Trump launched TrumpRx.gov in February as a price-comparison and discount site for generic and branded drugs, with an early emphasis on GLP-1 weight-loss medications from Eli Lilly and Novo Nordisk. The concept was straightforward: go to the site, find a lower cash price, pay less.

The catch was that those cash payments existed entirely outside your insurance. That matters because most health plans require you to hit a deductible before your coverage actually kicks in. A deductible is the minimum you must spend out-of-pocket before your insurer starts sharing costs. If TrumpRx purchases don't count toward that deductible, you're essentially paying twice: once at the discount window and once again, in the form of delayed insurance benefits, because the clock on your deductible never moves.

For someone with a $2,000 or $3,000 deductible, that gap isn't a technicality. It's real money.

What the settlement actually requires

Under the agreement, CVS's Caremark must count what patients spend through TrumpRx toward the deductibles of its health plans, once the regulatory framework for the program is in place. This closes the most significant structural flaw in the program for anyone whose coverage runs through a Caremark-administered plan.

The settlement also mirrors an earlier FTC deal with Cigna reached this year, and pushes Caremark in a similar direction on a separate, long-criticized practice: rebates. Drug companies pay rebates to pharmacy benefit managers after certain drugs are dispensed. Critics argue these payments create incentives for benefit managers to favor more expensive drugs on their formularies rather than cheaper alternatives, because bigger rebates flow from pricier medicines. The settlement requires CVS to offer its clients a plan option that doesn't rely on rebate payment models at all.

"The FTC under President Trump won't stand for anticompetitive behavior that drives up prices for American consumers," FTC Chairman Andrew Ferguson said in a statement.

Who benefits, and when

If you are enrolled in a health plan administered by Caremark, this settlement could eventually mean that a discounted TrumpRx purchase for, say, a diabetes medication or a weight-loss drug actually moves your deductible counter. That would give the program genuine value for insured people, not just the uninsured or those paying out of pocket by choice.

The timing carries a significant caveat. The deductible-counting requirement only takes effect once regulations are in place to support the TrumpRx program. That regulatory process has not concluded, and no date has been set. So the benefit is real but conditional.

The rebate reform is broader in potential scope. Pharmacy benefit managers administer drug coverage for tens of millions of Americans through employer plans, union plans, and government programs. If the opt-out from rebate models gains traction with large employers or insurers, it could, over time, shift which drugs get recommended and at what price. But large-scale behavior change in an industry this entrenched moves slowly.

The bigger picture

This settlement is the second of its kind in 2026, following Cigna's earlier agreement with the FTC. The pattern suggests the commission is applying consistent pressure across the pharmacy benefit management industry, a sector that has faced years of criticism for opacity and misaligned incentives. Whether the pressure translates into meaningfully lower drug costs depends on how aggressively clients actually exercise the new options they're being offered, and whether the TrumpRx regulatory framework arrives quickly enough to matter.

The mechanism is now in place. The question is whether the plumbing gets finished before the next deductible year begins.